An interesting idea does not automatically deserve another dollar. Intellectual Frontiers Capital tests the economics, searches for founders already pursuing the thesis, and backs the strongest evidence whether the opportunity began inside or outside the firm.
A founder selling into a health system does not lose on product alone. The buying committee may meet quarterly, the security review may take eleven weeks, and the budget line may already be spent. Capital prices those facts at the start instead of discovering them in month nine.
The firm forms theses, then looks for founders and companies already working on them. Founder conversations, traction, distribution, customer access, and operating capability are evidence. If somebody else is farther along or better positioned, backing that team is a better decision than recreating the work.
With a founder building on AI, we start by asking which entirely new forms of work the company makes possible. A product that makes an existing job faster competes with every other tool shaving the same minutes, and the savings get handed to the buyer at renewal. A company that reimagines care itself, using AI, devices, remote care, and new operating models, and then owns or partners in delivering that care, gets priced against the value of the new function. That is what we underwrite.
Some of the best opportunities originate outside Intellectual Frontiers. A founder may bring a thesis the firm never considered, independently reach a similar conclusion, or have a better execution path. The question is not who thought of it first. The question is where capital can support the strongest expression of the idea.
Capital should be comfortable concluding that somebody else should build the company. That is not a failure of originality. It is disciplined allocation. Only when the search fails, the evidence remains compelling, and no better-positioned operator exists does Studios become the likely next test.
Our care delivery capital reimagines how care is delivered, using AI, novel devices, and remote care, then owns the delivery model when possible or partners with the operators who can deliver it at scale. We run it in two vehicles: a small active fund building the foundations, and a larger fund in formation to back the clinicians who will use them.
Active now · Under $1M
A small, working fund that incubates the foundational ventures and shared services the rest of the portfolio will run on: demand intelligence, revenue operations, an execution layer for providers, and ambient measurement.
In formation · $25M starting point, perhaps as high as $50M
Back the clinicians rebuilding care delivery. An intelligence engine built on CMS and claims data decides whether the firm invests in a founder already in motion, takes selective control of an operator worth re-platforming, or builds the company itself.
What matters to a company selling clinical software, device connectivity, insurance automation, trials software, or marketplace infrastructure is getting through the door and getting past the review. The check is the easy part.
Portfolio positions in clinical workflow, device data, and payer automation can come with the money, so the company starts with a defensible claim instead of a roadmap.
People who have been through an FDA submission, an insurance integration, a trials platform rollout, or a large system replacement, and know where each one stalls.
Clearance slips and delayed state awards get modeled as normal events, so the plan survives them instead of assuming they will not happen.
One named owner, a written kill condition, and a scheduled review. Founders get an answer, including a no, rather than a slow fade.
A test that ran against production data: authorization histories, device telemetry, trial enrollment records, transaction logs. Market size tells us nothing we can act on.
Revenue against a real budget line. A health system that issued a purchase order against an operating budget has said more than ten that signed a letter of intent, and a research site paying monthly has said more than a vendor pilot it gets for free.
Someone who owns the outcome. Every position has a named operator with the authority to change course or exit, and the record shows who decided and on what evidence.
A clear account of what the founder, customer, co-investor, or limited partner taught the thesis. Capital-market evidence returns to the shared record instead of ending with the transaction.
Founders with a working system and at least one paying buyer in health delivery, medical devices, insurance operations, clinical trials, or digital marketplaces. Co-investors who want a partner that can read an audit trail and a 510(k) timeline. Health systems, insurers, and manufacturers with an internal project that ought to be a company.
Reading these makes the first call shorter, because our evidence standard is already on the page.
Test whether capital would accelerate a repeatable customer motion or merely extend the search for one.
Both funds, the intelligence engine behind them, and every company they back, in one register.
How we size a market we intend to enter, with the assumptions written down.
Concrete deployments in provider, device, trials, insurance, and marketplace settings.
The rights positions available to license into a funded company.
Send the thesis, the evidence behind it, and what would prove it wrong.
NewCapital
The seed and early-capital readiness tool gives a verdict on whether money would accelerate a repeatable customer motion or only extend the search for one.
UpdateCapital
The Capital page now says the firm tests whether money should move first, then backs the best founder or company working on a thesis, whether or not the firm created it.
NewCapital
Care Delivery Fund I is an active fund under $1M that incubates ten companies and programs, and Fund II is in formation, explored at $25M to $50M.
Put this to work
Prepare an investment screen around evidence, rights, distribution, economics, and the next proof point.
Completing this screen is not an offer or a promise to invest.
Nothing entered here is stored or sent. Review the prompt before sharing confidential, personal, patient, or privileged information.
You can leave any field blank. The prompt will mark it as not provided.
If the record survives your review, send the question, evidence, unknowns, and requested next step.